# A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment

> **NCT07220538** · PHASE4 · RECRUITING · sponsor: **Dr. Willmar Schwabe GmbH & Co. KG** · enrollment: 400 (estimated)

## Conditions studied

- Ischemic Stroke Hospitalized
- Impairment, Cognitive

## Interventions

- **DRUG:** Extract of Ginkgo Biloba Leaves Tablets 240 mg (2 x 40 mg, t.i.d.)
- **OTHER:** Standard of care (SoC) Group

## Key facts

- **NCT ID:** NCT07220538
- **Lead sponsor:** Dr. Willmar Schwabe GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-28
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07220538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07220538, "A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07220538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*